
13th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease 16-17 March 2018



Foreword by Professor Chris Thiemermann, FMedSci



Dear Friends and Colleagues,

It is my great pleasure to welcome you to the 13th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease at The Royal Society. Thank you once again to United Therapeutics for their continued support of the series via their provision of an unrestricted educational grant.

Since the inception of the series in 2006, we have strived to update you on the very latest research and clinical advances in PAH. The programme of the 13th JVMS includes a wide variety of important topics ranging from pathophysiology to risk assessment, prognosis, guideline implementation and patient stratification in patients with PAH to regulatory aspects relating to the registration of orphan drugs in PAH.

We look forward to hearing your thoughts on this year's presentations as well as learning about your personal experiences of working in this area. We are always open to receiving your suggestions of topics you would like to see included in future JVMS (2019-2021).

In the meantime, I and the rest of the organising team wish you a useful and enjoyable few days here at the Royal Society!

With warm regards,


Chris

Professor Chris Thiemermann, MD PhD FBPhS FRCP FMedSci Contact: c.thiemermann@qmul.ac.uk

Sir John Vane, FRS, Nobel Laureate

"It is sometimes said that the major discoveries have already been made and that there is nothing important left to find. This attitude is altogether too pessimistic. There are plenty of things left to discover. The trick is to find the right path from one to other."

John Vane



2 William Harvey Conferences

John Vane Memorial Symposium 3

16 March 2018

8.45-9.45am Registration, tea and coffee

9.45am Welcome

Chris Thiemermann, Queen Mary University of London, London, UK

Session I

Chairs: Chris Thiemermann, Queen Mary University of London, UK

Dario Vizza, La Sapienza University of Rome, Rome, Italy

10.00am Drug Development in Pulmonary Arterial Hypertension and the Orphan Drugs Regulation in Europe

Bruno Sepodes, University of Lisbon, Lisbon, Portugal

10.30am Refreshments

Session II

Chairs: Brendan Whittle, Queen Mary University of London, UK

Meinhard Kneussl, University of Vienna, Vienna, Austria

11.00am Three years experience with Oral Prostanoids: What have we learned?

Jim White, University of Rochester Medical Centre, New York, USA

11.30am Similarities and differences of IP-agonists and Prostanoids : The Basic Science Perspective

Lucie Clapp, University College London, London, UK

12.00pm Similarities and differences of IP-agonists and Prostanoids: The Clinical Perspective

Dario Vizza, La Sapienza University of Rome, Rome, Italy

12.30pm Lunch

Session III

2.30pm

Chairs: Paul Corris, Newcastle University, Newcastle, UK

Jim White, University of Rochester Medical Centre, New York, USA

2.00pm Novel Aspects of the Pathophysiology of Pulmonary Hypertension

Marlene Rabinovitch, Stanford University, Stanford, USA

Is there still enough evidence for Parenteral treatments in PH?

Irene Lang, Medical University of Vienna, Austria

3.00pm Is there a role for PRN inhaled Prostanoid-use to increase Exercise Capacity in PH?

Adaani Frost, Weill Cornell Medicine College, Houston, USA

3.30pm Refreshments

Session IV

Chairs: Robert Naeije, Universite Libre de Bruxelles, Belgium

Irene Lang, University of Vienna, Vienna, Austria

4.00pm Advances in determination of RV function in Pulmonary Hypertension by CMR imaging

Andrew Peacock, University of Glasgow, UK

4.30pm Exercise-induced PH: Treat or Don't treat?

David Systrom, Brigham and Women's Hospital, Boston, USA

5.00-6.30pm Meeting adjournment and Evening Reception at the Royal Society

17 March 2018

8.00am Tea and coffee

Session V

Chairs: Andrew Peacock, University of Glasgow, UK

Marc Humbert, Université Paris-Sud, Paris, France

9.00am Risk Assessment, Prognosis and Guideline Implementation in PAH

Olivier Sitbon, Université Paris-Sud, Paris, France

9.30am Management of WHO Group II PH due to Cardiac Diseases

Robert Naeije, Universite Libre de Bruxelles, Belgium

10.00am Management of WHO Group III PH due to Chronic Lung Disorders

Rajeev Saggar, University of Arizona, Phoenix, USA

10.30am Refreshments

Session VI

Chair: Olivier Sitbon, Université Paris-Sud, Paris, France

Marlene Rabinovitch, Stanford University, Stanford, USA

11.00pm Clinical phenotypes and survival of Pre-capillary Pulmonary Hypertension in Systemic Sclerosis

Marc Humbert, Université Paris-Sud, Paris, France

11.30pm Heart Failure with Preserved Ejection Fraction: Clinical study design and treatment

Mardi Gomberg-Maitland, Inova Fairfax Heart and Vascular Institute, Falls Church, USA

12.00pm Translation of Stratified Medicine for PAH into practice

Paul Corris, Newcastle University, Newcastle, UK

12.30pm Progress towards a Molecular Stratification of PAH

Martin Wilkins, Imperial College, London, UK

1.00pm Lunch

2.00pm Close of meeting

4 William Harvey Conferences

John Vane Memorial Symposium 5

John Vane Memorial Symposium 2017

The 12th John Vane Memorial Symposium drew both new and returnee' speakers and delegates to The Royal Society in London from 25 different countries; providing them with a forum to meet with colleagues and friends and discuss the very latest developments in PAH.

In addition to the many high-calibre presentations, which explored the latest thinking in the pathophysiology and treatment of the condition, the debate entitled "The PAH Patient" was extremely well received. We would like to thank all of the contributors and, indeed, all of the speakers for their greatly valued participation.

Professor Chris Thiemermann, CEO of William Harvey Research Limited and Faculty Chair of the John Vane Memorial Symposium said "It is always my great pleasure to work alongside friends and colleagues on this symposia series. The 12th symposium built on the success of previous years and delivered yet another valuable opportunity to learn about and discuss the very latest topics in PAH. We hope that by sharing the latest advances in treatment and by debating their experience with patients, nurses and doctors, we will ultimately improve both the clinical outcome and the quality of life of our patients".

Please see a selection of images from the 2017 symposium which we hope you will enjoy.



2017 Speaker faculty



Members of the 2017 delegation



Engaged participants



Friends and colleagues



Professor Paul Corri



Patient debate participants

William Harvey Research® Limited

Contract Research

WHRL has been leading the way as a contract research organisation (CRO) for the biotech and pharmaceutical sectors for over 20 years, both nationally and internationally. It offers a preclinical drug evaluation service, specialising in models of cardiovascular and inflammatory diseases. Many clients come to WHRL by recommendation, value the quality of the service provided and continue to entrust WHRL with their studies.

WHRL offers a highly differentiated service based on efficiency, reliability and quality. More than 120 disease models and a broad range of techniques are available. Following each study, which frequently is custom-designed to meet the specific needs of our clients, a comprehensive report of the findings is provided, which incudes all raw data, statistical analysis and interpretation of the results. This saves valuable time and money for clients, as well as directing them on the most appropriate next steps to develop their compound. WHRL's senior scientists also offer one-to-one discussions and advice on clients' preclinical testing needs. These benefits are not usually available through a conventional CRO.

Academic Fellowships

WHRL works with HCA International Ltd, which funds academic fellowships in biomedical research. These specialist medical trainees recruited by WHRL for academic research, primarily at Queen Mary University of London, additionally provide resident medical officer services to private hospitals in London, representing a considerable investment by the sector in academic biomedical research and high-quality patient care.

Scientific Conferences


WHRL arranges prestigious scientific meetings on recent developments in biomedical research. WHRL has more than 20 years' experience organising national and international scientific conferences, and established in 2006 the annual John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease. This highly successful meeting series attracts over 200 delegates each year from around 25 countries and is accredited with CPD points awarded by the Royal College of Physicians of the UK.

Shareholders

WHRL is a business wholly committed to furthering research into cardiovascular disease, endocrine disorders and inflammation for translational and therapeutic purposes. Its profits are gift aided to its majority shareholder, the William Harvey Research Foundation, which, in turn, awards grants for research in the above disease areas with the aim to facilitate therapeutic innovation and ultimately improve patient outcome and quality of life. Grants amounting to over £10m have been awarded by the WHRF to date. WHRL works primarily, but not exclusively, at the central London facilities of the William Harvey Research Institute at Barts Medical and The London School of Medicine & Dentistry, Queen Mary University of London (which is the minor, but equally important, shareholder of the company).

The Brand

William Harvey Research® is a trademark owned by WHRL. The company also owns the trademarks for William Harvey Conferences®, William Harvey Heart® and William Harvey Consulting® to name but a few.



6 William Harvey Conferences

John Vane Memorial Symposium 7

16-17 March 2018 Royal Society, London, UK

Faculty Chair

Professor Chris Thiemermann, Queen Mary University of London, London, UK

Session Chairs

Paul Corris, Newcastle University, UK Marc Humbert, Université Paris-Sud, France Meinhard Kneussl, University of Vienna, Austria Irene Lang, Medical University of Vienna, Austria Robert Naeije, Universite Libre de Bruxelles, Belgium Andrew Peacock, University of Glasgow, UK

Marlene Rabinovitch, Stanford University, USA Olivier Sitbon, Université Paris-Sud, France Chris Thiemermann, Queen Mary University of London, UK Dario Vizza, La Sapienza University of Rome, Italy Brendan Whittle, Queen Mary University of London, UK Jim White, University of Rochester, USA

Allocated 8 category 1 (external) CPD credits by the Federation of the Royal Colleges of Physicians of the United Kingdom.

www.williamharvey.co.uk



William Harvey Research Limited John Vane Science Centre Charterhouse Square London EC1M6BQ **United Kingdom**

Tel: +44 (0)20 7882 8808 email: whrl@qmul.ac.uk



♣ @JVMSseries



@JVMSseries



(O) @JVMSseries

Registered in England – Registration No 2437946 Registered office: Charterhouse Square, London EC1M 6BQ

JVMS 2006-2018: Contributor Faculty

Amrita Ahluwalia Stephen L. Archer Andrew Baker Robyn Barst Michael Bauer Raymond Be<u>nza</u> Robert Bourge Ghazwan Butrous Adrian Chester Lucie Clapp Gerard Coghlan John Cooke Paul Corris Michele D'Alto Marion Delcroix Chris Denton Laurence Dewachter Pisana Ferrari Al Fishman Rod Flower Adaani Frost Sean Gaine Nazzareno Galie Francoise Dignat George Ardeschir Ghofrani Adam Giangreco Simon Gibbs Wendy Gin-Sing Mark Gladwin Mardi Gomberg-Maitland Mike Grocott Ekkehard Gruening Richard Gryglewski Christophe Guinabert Sheila G. Haworth Tim Higenbottam Adrian Hobbs Luke Howard Marc Humbert Carlos Jardim Roger Jeffs

Martin Johnson Shaf Keshavjee Darrell Kotton Mordechai Kramer Meinhard Kneussl Christopher Lambers Irene Lang Peter Lelkes Marilyne Levy Vincenzo Libri James Lordan Paolo Macchiarini Mandy MacLean Hiromi Matsubara Vallerie McLaughlin Saul McLaughlin Sanjay Mehta Jane Mitchell Nick Morrell Edward Morrisey Helder Mota-Filipe Christine Mummery Monty Mythen Robert Naeije John Newman Laura Niklason Luke O'Neill Andrea Olschewski Mark Ormiston Harald Ott Clive Page Andrew Peacock Joanna Pepke-Zaba Dame Julia Polak Ioana Preston Soni Pullamsetti Marlene Rabinovitch Emma Rawlins Stuart Rich Franz Rischard Stephan Rosenkranz Nadia Rosenthal

Jenesis Rothblatt Lewis Rubin Rajeev Saggai Sami Said John Sanderson Ralph Schermuly Karsten Schrör Bruno Sepodes Gerald Simonneau Oliver Sitbon David Smadja Thomas Smith Rogério So<u>uza</u> Randy Sprague Duncan Stewart Ken Suzuki David Systrom Nick Talbot Victor Tapson Chris Thiemermann Patricia Thistlethwaite Richard Trembath Jean-Luc Vachiéry Rebecca Vanderpool Dario Vizza Anton Vonk-Noordegraff Robert Voswinckel David Warburton Tim Warner Aaron Waxman Daniel Weiss Norbert Weissmann Jim White Brendan Whittle Martin Wilkins Magdi Yacoob Sir Magdi Yacoub Mordechai Yigla Jason Yuan Dianne Zwicke